A Retrospective Cohort Study on the Qifu Huazhuo Recipe for the Treatment of Gout Due to Spleen and Kidney yang Deficiency
Objective:To explore the clinical efficacy and safety of Qifu Huazhuo prescription in the treatment of gout due to spleen and kidney yang deficiency.Methods:Patients with gout due to spleen and kidney yang deficiency who visited the outpatient clinic of the Department of Rheumatology of Guangdong Provincial Hospital of Traditional Chinese Medicine and the outpatient clinic of the Department of Rheumatology and Hematology of Guangdong Provin-cial Hospital of Traditional Chinese Medicine Zhuhai from September 2020 to August 2022 were enrolled and divided into a treatment group and a control group based on whether they took Qifu Huazhuo prescription as the exposure fac-tor.The general data of the patients were collected,and the differences in uric acid change rate,uric acid compliance rate and safety indicators between the two groups after treatment were compared.Cluster analysis was used to explore the dominant population in the treatment group.Results:A total of 139 gout patients were included,including 62 cases(44.6%)in the control group and 77 cases(55.4%)in the treatment group.The uric acid change rate in the treatment group was significantly lower than that in the western medicine group;the uric acid compliance rate in the treatment group was better than that in the western medicine group,and the difference was statistically significant.The number of patients with abnormal renal function in the treatment group decreased after treatment compared with before treat-ment,but there was no statistical difference.Cluster analysis showed that the Chinese and Western medicine group had a better uric acid-lowering effect on gout patients with an average age of 48.5 years and an average disease course of 2.42 years.Conclusion:For patients with spleen and kidney yang deficiency who have poor uric acid control using Western medicine,Qifu Huazhuo prescription combined with uric acid-lowering drugs is an effective intensive treatment meth-od;Qifu Huazhuo prescription combined with uric acid-lowering drugs is more suitable for patients with spleen and kidney yang deficiency gout who are around 48 years old and have a shorter disease course.
GoutQifu Huazhuo prescriptionSpleen and kidney Yang deficiencyRetrospective cohort study
国家科技期刊平台
NSTL
万方数据
